| Autor: |
Grechukhina KS; Lomonosov Moscow State University.; Loginov Moscow Clinical Scientific Center., Chebotareva NV; Sechenov First Moscow State Medical University (Sechenov University)., Krasnova TN; Lomonosov Moscow State University. |
| Jazyk: |
ruština |
| Zdroj: |
Terapevticheskii arkhiv [Ter Arkh] 2020 Jul 09; Vol. 92 (6), pp. 93-98. Date of Electronic Publication: 2020 Jul 09. |
| DOI: |
10.26442/00403660.2020.06.000672 |
| Abstrakt: |
Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases. The most important is vascular endothelium growth factor (VEGF) and its receptors (VEGFR1/2) in angiogenesis processes. Nowadays antiangiogenic agents (which inhibit VEGF like bevacizumab neither VEGFR2 like ramucirumab) are widely used in very different chemotherapeutic regimens in clinical oncology. The signalling pathway VEGF-VEGFR plays a crucial role in supporting of adequate kidney function. Appearance of antiangiogenic drugs led to adverse nephrotoxic effects: arterial hypertension, proteinuria, rarely nephrotic syndrome, and kidney dysfunction. Various hystological variants of nephropathy are described, however, in most cases, signs of thrombotic microangiopathy of the renal vessels are noted. This literature review discusses mechanisms, clinical and morphological aspects of nephropathy associated with antiangiogenic drugs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
